10 results about "Vitamin k" patented technology

The application belongs to the field of photodynamic therapy, and specifically discloses a vitamin K co-crystal material for photodynamic therapy and a preparation method thereof. The vitamin K co-crystal material takes vitamin K as an electron acceptor, and the two carbonyl groups at the para positions of the vitamin K quinoid six-membered ring make the vitamin K exhibit electron deficiency, form an organic charge transfer complex with the electron acceptor, and self-assemble to form a co-crystal, so that the absorption spectrum of the system is widened, a wider wave band of light is more effectively utilized, the photodynamic therapy response wavelength of the vitamin K is adjusted from the ultraviolet region to the visible region and the near infrared region, the problem of low penetration depth and light damage caused by photodynamic therapy using light in the ultraviolet region is avoided, and the vitamin K has excellent photodynamic performance and good application prospects in surface sterilization and disinfection, treatment of body surface infection, and directional cancer treatment based on visible light or near infrared light.

The invention discloses application of vitamin K in preparation of a medicine for treating paravertebral muscle adiposis of obese patients. The core of the application is to reverse fat infiltration in paravertebral muscles (such as multifidus muscle, erector spine muscle and lumbar major muscle) of an obese patient, so that the structure and function of a vertebral endplate are improved, the stability of the spine is enhanced, and degeneration of the spine intervertebral disc of the obese patient is relieved. The method has the advantages of non-invasiveness, high safety and the like, and is suitable for treating lumbago diseases related to long-term obesity management and paravertebral muscle adiposis.

The invention discloses an intelligent micro-pressure hemostatic cotton ball patch which comprises a contact layer, a pressure control layer, a fixing layer and an intelligent monitoring system. The contact layer is a drug-loaded hydrogel cotton ball, contains chitosan and vitamin K, and expands by 20% after sucking blood; the pressure control layer is provided with eight groups of springs with the initial pressure of 15mmHg, and is provided with a three-color pressure visual window; the fixing layer is a medical silica gel bionic suction cup, and the stripping force is larger than 3N. The intelligent monitoring system comprises a color-changing timing ring (changing from white to blue within 5 minutes) and an errhysis alarm module (a conductive fiber triggers a vibration motor and an LED lamp). The diameter of the device is 3 cm, the thickness is 1.2 cm, Bluetooth transmission and block chain evidence storage can be integrated, the hemostasis efficiency is improved by 55% or above, the early warning speed is increased by 5-10 times, and the device is suitable for hemostasis after venipuncture.

This invention belongs to the field of microbial technology, specifically disclosing a probiotic composition and its application. The probiotic composition provided by this invention includes at least two of the following: prebiotics, vitamin K, and zinc, as well as *Bifidobacterium longum* subsp. infantis i18. The probiotic composition provided by this invention can not only effectively promote the growth and development of premature mice, but also optimize the intestinal flora structure and promote intestinal development in premature infants by reducing the abundance of harmful bacteria and increasing the relative abundance of beneficial bacteria; simultaneously, it can downregulate the levels of pro-inflammatory factors TNF-α and IL-6, reducing intestinal inflammation and lowering the risk of necrotizing enterocolitis in premature infants. This invention can be applied to the preparation of products that improve the intestinal flora of premature infants, promote their growth, or prevent intestinal inflammation.

A synergistic combination of agents with a protective effect on vascular endothelial function is disclosed, for use in the treatment and prevention of complications of anticancer therapies.

The present invention aims to provide an epidermal barrier function improving agent and an aromatic hydrocarbon receptor activator containing Artemisia princeps extract and / or vitamin K as active ingredients. [Solution] The present invention provides an epidermal barrier function improving agent and an aromatic hydrocarbon receptor activator containing Artemisia princeps extract and / or vitamin K as active ingredients.

The invention relates to a cosmetic and / or pharmaceutical composition for preventing or reducing hair loss of a mammal due to stress and for use in the treatment of a hair growth disease or hair growth disorder exacerbated by stress.

The application relates to a CePO4@RuO2@Cu-MOF heteronano-wire and a preparation method thereof and application thereof in selective oxidation synthesis of vitamin K intermediates, and belongs to the technical field of nano functional materials and catalysis. The CePO4@RuO2@Cu-MOF heteronano-wire is a one-dimensional ternary structure, the one-dimensional CePO4 nano-wire is used as a core base material, the middle layer is RuO2 nano active sites in-situ heterogeneously grown, and the outer layer is a Cu-MOF porous shell layer in-situ grown; a continuous and firm hetero-interface is formed among the three phases. The material obtained by the application exhibits super-high product selectivity, excellent catalytic activity and super-long cycle stability in the reaction of catalyzing selective oxidation of 2-methylnaphthalene to prepare a vitamin K key intermediate through the channel limiting effect and interface electronic coupling effect of the outer layer Cu-MOF.

A preparation method for a vitamin K1 injection package, and a vitamin K1 injection package. The preparation method comprises filling, nitrogen flushing, stoppering and rod screwing; in the nitrogen flushing step, sterile nitrogen is introduced into a glass cartridge (1) to reduce oxygen content inside the glass cartridge (1) to 2.0% or less; in the stoppering step, the glass cartridge (1) is evacuated, thereby drawing a plunger (2) into the glass cartridge (1), and the headspace volume is controlled to 0.1-0.2 ml.

The present application relates to topical formulations comprising Compound-Ior its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.